European Hematology Association Congress | Conference

Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

June 17th 2018

The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.

Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML

June 17th 2018

Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

June 16th 2018

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

June 16th 2018

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.

Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML

June 16th 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the results of quizartinib in patients with relapsed/refractory acute myeloid leukemia.

Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL

June 16th 2018

Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

Compound CAR T-Cell Therapy Shows Promise for AML

June 16th 2018

A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.

Dr. Garcia-Sanz on Brentuximab Vedotin Plus ESHAP in Hodgkin Lymphoma

June 15th 2018

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses the results of brentuximab vedotin (Adcetris) plus ESHAP followed by autologous stem cell transplant in patients with relapsed/refractory Hodgkin lymphoma.

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

June 15th 2018

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma

June 15th 2018

PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

June 15th 2018

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

June 28th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

June 28th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

Chemotherapy-Free Triplet Achieves 100% Response Rates in 3 Lymphoma Subtypes

June 27th 2017

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

Ibrutinib/Venetoclax Yields Dramatic Blood Response in Patients With Relapsed/Refractory CLL

June 26th 2017

Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma

June 25th 2017

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Polatuzumab Vedotin Demonstrates Durable Reponses in Follicular Lymphoma, DLBCL

June 25th 2017

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML

June 25th 2017

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

June 25th 2017

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL

June 25th 2017

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.